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Abstract:Cytokeratin 17 (CK17), a basal/myoepithelial cell keratin, appears to play an important role in the 
progression of several human malignancies. Increased CK17 expression has previously described in cases of 
papillary thyroid carcinoma (PTC). However, no studies to date have investigated the clinical significance of CK17 
expression in patients with PTC. The aim of this study was to compare the expression of CK17 in patients with PTC 
with that observed in normal thyroid tissue and benign thyroid lesions, and to examine the relationship between 
CK17 expression and clinicopathologic characteristics of patients with PTC. CK17 protein expression was evaluated 
by immunohistochemistry on tissue microarrays containing thyroid tissue samples from 108 PTCs, 16 nodular goi-
ters, and 81 healthy controls. Sixty-five of the 108 (60.2%) PTC tissue samples exhibited positive CK17 expression, 
whereas all nodular goiters and normal thyroid tissue samples showed a complete absence of CK17 immunoreactiv-
ity. The difference in frequency of CK17 positivity between PTC (65/108, 60.2%), normal thyroid tissue (0/81, 0.0%), 
and benign thyroid lesions (0/16, 0.0%) was statistically significant (P<0.001). Positive CK17 expression in PTC was 
significantly associated with the presence of lymph node metastasis (P=0.024) and higher pN stage (P=0.028). 
Expression of CK17 is significantly increased in cases of PTC compared to normal tissue and benign thyroid lesions, 
and CK17 overexpression is associated with the presence of lymph node metastasis in patients with PTC. These 
findings suggest that CK17 is involved in the development and metastasis of PTC.
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Introduction
Papillary thyroid carcinoma (PTC) constitutes 
85-90% of all malignant thyroid neoplasm [1, 
2]. Generally, PTC is relatively indolent and its 
long-term outcomes are favorable with a sur-
vival rate >90% [1]. However, some PTCs dis-
play aggressive features; certain clinicopatho-
logic characteristics such as advanced age, 
large tumor size, and the presence of extrathy-
roidal extension or cervical lymph node metas-
tasis have been suggested as poor prognostic 
factors [3-5]. Similar to other human malignan-
cies, tumorigenesis and progression of PTC are 
caused by numerous reproductive, environ-
mental, and genetic risk factors. Therefore, it is 
of great importance to identify the genetic 
changes and molecular events involved in the 
initiation, progression, and metastasis of PTC.
Most eukaryotic cells contain cytoskeletal sys-
tem consisting of intermediate filaments in their 
cytoplasm. Among the intermediate filaments, 
keratins are outstanding due to its high molecu-
lar diversity. Keratin filament bundles insert at 
desmosomes at cell-cell contact sites of kerati-
nocytes of the epithelial cells. This feature sug-
gests that keratins play a major functional role 
in the integrity and mechanical stability of epi-
thelial cell morphology and intercellular feature 
[6]. 
Cytokeratins show characteristic expression 
patterns in epithelial cells according to origin of 
cell, differentiation, and its role. Cancers fre-
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quently retain the expression patterns of cyto-
keratins that are associated with that particu-
lar organ cell type. Thus, cytokeratin profiling 
provides useful information for detecting the 
primary site of carcinomas that have 
metastasized.
Cytokeratin 17 (CK17), regarded as a basal/
myoepithelial cell keratin, was originally identi-
fied as a major cytokeratin in cutaneous basal 
cell carcinomas but not in normal epidermis 
[7]. In normal human epithelia, CK17 expres-
sion is observed in the respiratory tract, urinary 
tract, and various glands [8, 9]. Previous stud-
ies have demonstrated that CK17 can be a spe-
cific marker of adenocarcinomas of the biliary 
tract, and that it is a useful for distinguishing 
pancreatobiliary adenocarcinoma from other 
adenocarcinomas arising from digestive tract, 
reproductive tract, lung, and prostate [10-12]. 
In addition, several studies have shown a sig-
nificant relationship between CK17 expression 
and prognosis in patients with gastric adeno-
carcinoma and ovarian carcinoma [13, 14]. 
However, the expression patterns and involve-
ment of CK17 in PTC are still unclear, and the 
clinical significance of CK17 expression in 
patients with PTC has yet to be investigated.
The aim of this study was to compare the 
expression of CK17 in cases of PTC with that 
observed in normal thyroid tissue and benign 
thyroid lesions, and to examine the relationship 
between the expression of CK17 and clinico-
pathologic characteristics of patients with PTC.
Materials and methods
Patients and tissue specimens
We retrospectively reviewed 108 cases of PTC 
and 16 cases of nodular goiter from records 
obtained from the Department of Pathology, 
Kangbuk Samsung Hospital, Sungkyunkwan 
University School of Medicine, Seoul, Republic 
of Korea. Formalin-fixed, paraffin-embedded 
(FFPE) tumor tissue blocks were sectioned and 
stained with hematoxylin and eosin (H&E). The 
original H&E-stained slides were reviewed by all 
authors, and a diagnostic consensus was 
achieved in all cases. For PTC cases, clinico-
pathologic characteristics including age, gen-
der, size of tumor, multifocality, presence of 
extrathyroidal extension, lymph node metasta-
sis, and/or distant metastasis, tumor-node-
metastasis (TNM) stage, and the presence of a 
BRAF mutation were evaluated by reviewing 
patient medical records. A total of 81 normal 
thyroid tissue samples were collected for com-
parison of immunoreactivity. The Institutional 
Review Board at Kangbuk Samsung Hospital 
reviewed and approved this study (2014- 
01-002).
Construction of tissue microarray
The surgical specimens were fixed in 10% buff-
ered formalin, processed, and embedded in 
paraffin using a standard protocol. All H&E 
stained slides were reviewed, and the most rep-
resentative tumor area was carefully selected 
and marked on individual FFPE blocks. The 
most representative tissue core (2 mm diame-
ter) was then obtained from each tumor speci-
men and was manually arrayed in a recipient 
paraffin block by two pathologists (S.-I.D. and 
S.W.C.). The assembly was held in an X-Y posi-
tion guide with a 1-mm increment between the 
individual samples, and the instrument was 
used to create holes in a recipient paraffin 
block with defined array cores. The fit needle 
was used to transfer the tissue cores into the 
recipient block. The percentage of tissue cores 
containing tumor tissue was greater than 70%. 
To compare the expression patterns of CK17, 
81 samples of normal thyroid tissue were also 
obtained. 
Immunohistochemistry
Immunohistochemical staining was performed 
on 3 μm-sectioned TMA blocks using a com-
pact polymer method (Bond Intense Detection 
kit, Leica Biosystems, Newcastle, UK). The sec-
tions were deparaffinized and dehydrated using 
a graded series of ethanol solutions. 
Endogenous peroxidase activity was halted 
through incubation with 0.3% hydrogen peroxi-
dase and methanol for 20 min. Following a 
rinse in phosphate-buffered saline, the tissue 
sections were processed in a citrate buffer 
(0.01 M, pH 6.0) inside a heat-resistant plastic 
container. Sections were then irradiated in a 
domestic microwave oven for 20 min and 
allowed to cool at room temperature. The pri-
mary antibody used was CK17 (1:200; Dako, 
Glostrup, Denmark). The sections were incu-
bated with primary antibody overnight at 4°C, 
followed by the secondary antibody. The nega-
tive controls were stained without primary 
antibody.
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Immunoreactivity was independently scored by 
two board-certified pathologists (H.-S.K. and 
J.-J.L.). Following previous studies, the number 
of positive cells is quantified as follows: 0, no 
positive cells present; 1+, scattered positive 
cells present amounting to less than 1%; 2+, 
1-10% of lesional cells positive; 3+, 10-50% of 
lesional cells positive; 4+, more than 50% of 
lesional cells positive [15, 16]. When a discrep-
ancy occurred between the two pathologists, 
the tissue sample was reviewed together for a 
consensus opinion.
Detection of the BRAFV600E mutation
For the detection of the BRAFV600E mutation, 
nucleic acids from fresh thyroid tissue obtained 
from patients who had given informed consent 
were isolated using a DNA extraction kit 
(Qiagen, Hilden, Germany) according to the 
manufacturer’s protocol. Briefly, isolated nucle-
ic acids were mixed with a polymerase chain 
reaction (PCR) master mix from a Seeplex 
BRAFV600E ACE detection kit (Seegene Inc., 
Seoul, Republic of Korea). The mixed samples 
were immediately placed in a preheated (94°C) 
thermal cycler for 15 min, and PCR was carried 
out using the recommended program in a 
GeneAmp PCR 9700 system (Applied Bio- 
systems, Foster City, CA, USA). The cycling 
amplification program consisted of 35 cycles: 
denaturation for 30 s at 94°C, annealing for 30 
s at 63°C, and extension for 1 min at 72°C. The 
amplified PCR products were loaded onto a 2% 
agarose gel and were visualized with SafeView 
Stain (Applied Biological Materials Inc., 
Richmond, BC, Canada). The BRAF mutation 
was detected with a Gel Documentation sys-
tem (Bio-Rad Laboratories Inc., Hercules, CA, 
USA).
Statistical analysis
Pearson’s chi-square tests or Fisher’s exact 
tests were performed to compare CK17 expres-
sion between normal thyroid tissue, nodular 
goiters, and PTCs, and to determine whether 
the status of CK17 expression in PTC is associ-
ated with clinicopathologic characteristics 
including age, gender, size of the tumor, multifo-
cality, presence of extrathyroidal extension or 
lymph node metastasis, and/or the presence of 
a BRAF mutation. The linear-by-linear associa-
tion test was used to examine the relationship 
between CK17 expression status and pT, pN, 
and TNM stage. The receiver-operating charac-
teristic curve was generated to divide the data 
into separate groups to allow for comparisons. 
Using the receiver-operating characteristic 
curve analysis, we determined 10% to be the 
cut-off point for classifying cases into CK17-
positive PTCs versus CK17-negative PTCs. 
Statistical analyses were performed using the 
SPSS Software Package (version 18.0; IBM 
SPSS, Chicago, IL, USA). Statistical significance 
was set at P<0.05.
Results
Patient characteristics
The mean age of patients at the time of diagno-
sis was 42.7 years (range, 23-73). The mean 
tumor size was 0.95 cm (range, 0.2-5.5 cm), 
and 79 cases (73.1%) were diagnosed as micro-
papillary carcinomas. Multifocal PTCs were 
observed in 25 cases (23.1%). Extrathyroidal 
tumor extension was noted in 52 cases (48.1%). 
The pT category distribution was as follows: 
pT1, 55 (50.9%); pT2, 1 (0.9%); pT3, 52 (48.1%). 
The pN category distribution was as follows: 
pN0, 46 (42.6%); pN1a, 54 (50.0%); pN1b, 8 
(7.4%). Twenty-eight cases were classified as 
stage I (75.9%), 72 as stage III (66.7%), and 8 
as stage IV (7.4%). BRAF mutational analysis 
was performed in 69 (63.9%) cases, 58 (84.1%) 
of which were positive.
Expression of CK17 in PTC and its relationship 
with clinicopathologic characteristics
CK17 immunoreactivity was completely absent 
in all of the nodular goiter (16.0%) and normal 
thyroid tissue samples (81.0%). In contrast, 65 
of the 108 (60.2%) PTC tissue samples exhibit-
Table 1. Expression of CK17 in normal thyroid tissue, nodular goiters and PTC
No. of patients (%)
P-value
0 1+ 2+ 3+ 4+
Normal thyroid 81 (100.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) <0.001a*
Nodular goiter 16 (100.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) <0.001b*
PTC 38 (35.2) 5 (4.6) 18 (16.7) 20 (18.5) 27 (25.0)
aPTC versus normal thyroid tissue; bPTC versus nodular goiter; *Statistically significant.
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ed positive CK17 expression. The difference in 
frequency of CK17 positivity between PTC and 
normal and benign thyroid tissues was statisti-
cally significant (P<0.001; Table 1). The expres-
sion of CK17 was more frequently detected in 
neoplastic papillae and individual tumor cells 
within a desmoplastic stroma (Figure 1). In 
some cases, immunoreactivity was also seen in 
the tumor cells lining papillary structures within 
the bulk of the tumor.
The association between CK17 expression and 
clinicopathologic characteristics of PTC was 
further analyzed, as shown in Table 2. Positive 
CK17 expression in PTC was significantly asso-
ciated with the presence of lymph node metas-
tasis (P=0.024) and higher pN stage (P=0.028).
Discussion
To our knowledge, this is the first study to exam-
ine the association of CK17 expression with 
clinicopathologic characteristics in patients 
with PTC. Although 2 previous studies have 
reported CK17 expression in thyroid tissues 
[15, 16], there is no available data on clinico-
pathologic associations with CK17 expression 
in patients with PTC.
CK17 is a low molecular weight keratin that 
belongs to the acidic type I CK family with a 
molecular mass of 48 KDa, and its counterpart 
CK subtype is considered to be K6b [17]. 
Expression of CK17 has been shown in various 
normal epithelial cells such as myoepithelial 
cells, basal cells of transitional and pseu-
dostratified respiratory and urinary tract epithe-
lium, stratified squamous epithelium of skin in 
early developmental stages, and subsets of 
hair shaft epithelia [8, 9, 18].
By contrast, in some normal tissues, including 
thyroid tissue, CK17 expression has been 
Figure 1. CK17 immunostaining results in PTC (A-D) and nodular goiter (E). The expression was observed in the cy-
toplasm of tumor cells. (A) Few tumor cells show CK17expression (1+). (B) Less than 10% of PTC cells express CK17 
(2+). (C) The tumor cells showing CK17 expression are easily observed but less than 50% (3+). (D) Diffuse strong 
CK17 expression in PTC (4+). Regardless the expression rate, all CK17 positive cells show storing intensity. (E) None 
of the nodular goiter cases shows CK17 expression.
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reported to be absent. Chu et al. reported no 
CK17 expression in normal thyroid tissue, and 
Yang et al. showed CK17 expression in pancre-
atobiliary carcinomas but no CK17 expression 
in normal pancreatobilary cells or normal thy-
roid follicular cells [19, 20]. Consistent with pre-
vious data, we demonstrated an absence of 
CK17 expression in normal thyroid tissue sam-
ples. Instead, we observed significantly 
increased CK17 immunoreactivity in PTC com-
pared to normal follicular cells. This finding was 
similar to a previous study that showed no 
CK17 mRNA in normal oral squamous epitheli-
um, but significant up-regulation of CK17 mRNA 
in oral squamous cell carcinoma [21]. Another 
study showed no CK17 expression in normal 
oral mucosa, and 100% positivity in carcinoma 
in situ and squamous cell carcinoma [22]. In 
addition, Ide et al. reported 49.5% positivity of 
CK17 in cases of gastric carcinoma but not in 
significant relationship between CK17 expres-
sion and poor prognosis in cases of gastric car-
cinoma, epithelial ovarian carcinoma, and oral 
squamous cell carcinoma [13, 14, 22]. In addi-
tion, CK17 has been correlated with poor histo-
logical differentiation, short overall and dis-
ease-free survival in invasive ductal carcino-
mas, and adverse effects on overall and dis-
ease-free survival in triple-negative breast 
cancer [26, 27].
Chang et al. showed that downregulation of 
CK17 gene expression in keratinocytes using 
RNAi and antisense technology may be an 
effective treatment option for patients with 
psoriasis [28]. Further evaluation is required to 
verify whether inhibition of CK17 can be used 
as a therapeutic option in malignant tumors 
that exhibit CK17 overexpression, as well as to 
characterize the functional role of CK17 in 
tumor progression. 
Table 2. Relationship between CK17 expression and clini-
copathologic characteristics of patients with PTC
Characteristics
No. of patients (%)
Positive Negative P-value
Age (years) ≤45 43 (62.3) 26 (37.7) 0.547a
>45 22 (53.4) 17 (46.6)
Gender Man 23 (67.6) 11 (32.4) 0.283a
Woman 42 (56.8) 32 (43.2)
Size of tumor (cm) ≤1.0 47 (59.5) 32 (40.5) 0.809a
>1.0 18 (62.1) 11 (37.9)
Multifocality Multiple 16 (64.0) 9 (36.0) 0.657a
Single 49 (59.0) 34 (41.0)
Extrathyroidal extension Present 34 (65.4) 18 (34.6) 0.287a
Absent 31 (55.4) 25 (44.6)
Lymph node metastasis Present 43 (69.4) 19 (30.6) 0.024a*
Absent 22 (47.8) 24 (52.2)
Distant metastasis Present 6 (75.0) 2 (25.0) 0.473a
Absent 59 (59.0) 41 (41.0)
pT stage pT1 30 (54.5) 25 (45.5) 0.254b
pT2 1 (100.0) 0 (0.0)
pT3 34 (65.4) 18 (34.6)
pN stage pN0 22 (47.8) 24 (52.2) 0.028b*
pN1a 37 (68.5) 17 (31.5)
pN1b 6 (75.0) 2 (35.0)
TNM stage group I-II 13 (46.4) 15 (53.6) 0.084a
III-IV 52 (65.0) 28 (35.0)
BRAF mutation Present 33 (56.9) 25 (43.1) 0.680a
Absent 7 (63.6) 4 (36.4)
aChi-square test or Fisher’s exact test; bLinear-by-linear association test; 
*Statistically significant.
normal gastric mucosa, and Wang et 
al. reported a significantly higher level 
of CK17 mRNA and protein expression 
in ovarian epithelial cancers com-
pared with noncancerous tissues [13, 
14]. Finally, Guelstein et al. demon-
strated CK17 positivity in all urothelial 
carcinomas examined in their study, 
in contrast to the negative expression 
observed in normal urothelium [13, 
14, 23].
Recently, CK17 has been shown to 
participate in cell growth and sizing of 
keratinocytes by regulating protein 
synthesis. Cell growth is concomitant-
ly stimulated after serum-dependent 
cytoplasmic translocation of 14-3-3γ 
from the nucleus, which requires 
mammalian rapamycin (mTOR) activi-
ty and two amino acid residues locat-
ed in the N-terminal head domain of 
CK17. In response to DNA damage, 
14-3-3γ has been primarily regarded 
as a potential tumor suppressor gene 
that is upregulated by p53. However, 
its role in the Akt/mTOR signal activa-
tion seems to be related to malignant 
changes in the tissue [24, 25].
We also found a significant associa-
tion between CK17 expression and 
the presence of lymph node metasta-
sis as well as a higher pN stage. There 
have been several studies showing a 
CK17 overexpression in PTC
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In conclusion, we demonstrated that expres-
sion of CK17 is significantly increased in cases 
of PTC compared to normal and benign thyroid 
tissues, and that CK17 overexpression is asso-
ciated with the presence of lymph node metas-
tasis and advanced N stage. These findings 
suggest that CK17 plays an important role in 
the development and metastasis of PTC.
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